ABT Q3 FY2026 earnings call — BigGo Finance

Abbott Laboratories (ABT) reported Q3 2026 sales growth of 7% YoY, with adjusted EPS of $1.42, meeting expectations. Growth was driven by diagnostics, medical devices, and nutrition. The company plans to spin off its nutrition business, expected to complete by the end of 2027, with the new entity having $8.5B in annual sales. Abbott revised its full-year 2026 sales growth guidance to approximately 6%, with Q4 growth just above 8%.

Original reporting
Published Oct 21, 2026, 3:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ABT
Bullish
high confidence
Mentioned
$ABT
Relevance
8/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$ABTBullishMed
01

Why it matters

The earnings beat and spin‑off announcement together create a fresh catalyst for price movement.

02

Market read

The combination of solid earnings and a strategic spin‑off provides actionable insight for traders focusing on health‑care equities.

03

What to watch

Exact timing of the spin‑off and regulatory approvals may delay expected benefits.

Relevance 8/10Novelty 8/10Timing: today

Background

Abbott's Q3 earnings call provided detailed segment performance and introduced a major corporate restructuring.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott reported Q3 FY2026 results with 7% sales growth, adjusted EPS $1.42 and announced a tax‑free spin‑off of its nutrition business.

Expected impact

likely modest upside as investors price in higher margins and the spin‑off premium.

Evidence & confidence

Strong top‑line, margin expansion, and a clear value‑creation plan from the nutrition spin‑off provide a clear catalyst.

Market effects

Nutrition and health‑care sectors may see re‑rating as Abbott separates a pure‑play nutrition company.

U.S. healthcare stocks could benefit from the spin‑off narrative.

Limited to investors tracking large‑cap US health‑care and spin‑off opportunities.

Counterpoint

Spin‑off execution risk and potential dilution could weigh on the stock if integration challenges arise.

Key entities

  • Abbott Laboratories

    US‑listed health‑care conglomerate reporting Q3 FY2026 results.

  • Daniel Salvadori

    Group President of Established Pharmaceuticals and Nutrition Products, appointed CEO of the future nutrition spin‑off.

Related articles

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

$ABTMed

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.